Similar articles for PMID: 30850506

Year	Number of Results
1995	1
1999	1
2001	1
2002	1
2003	3
2005	3
2006	3
2007	5
2008	5
2009	6
2010	6
2011	5
2012	7
2013	11
2014	14
2015	14
2016	20
2017	18
2018	9
2019	15
2020	18
2021	18
2022	31
2023	30
2024	22
2025	0

1

¹¹¹In-Pentetreotide Scintigraphy Versus ⁶⁸Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden.

Hope TA, Calais J, Zhang L, Dieckmann W, Millo C. Hope TA, et al. J Nucl Med. 2019 Sep;60(9):1266-1269. doi: 10.2967/jnumed.118.223016. Epub 2019 Mar 8. J Nucl Med. 2019. PMID: 30850506 Free PMC article. Clinical Trial.

2

The association between lesion tracer uptake on 68Ga-DOTATATE PET with morphological response to 177Lu-DOTATATE therapy in patients with progressive metastatic neuroendocrine tumors.

Metser U, Eshet Y, Ortega C, Veit-Haibach P, Liu A, K S Wong R. Metser U, et al. Nucl Med Commun. 2022 Jan 1;43(1):73-77. doi: 10.1097/MNM.0000000000001488. Nucl Med Commun. 2022. PMID: 34887370

3

Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.

Jois B, Asopa R, Basu S. Jois B, et al. Clin Nucl Med. 2014 Jun;39(6):505-10. doi: 10.1097/RLU.0000000000000429. Clin Nucl Med. 2014. PMID: 24662668

4

Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.

Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, Lakhani V, Baum RP, Berlin J, Smith GT, Graham M, Sandler MP, Delbeke D, Walker RC. Deppen SA, et al. J Nucl Med. 2016 May;57(5):708-14. doi: 10.2967/jnumed.115.163865. Epub 2016 Jan 14. J Nucl Med. 2016. PMID: 26769865 Free PMC article.

5

Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.

Putzer D, Kroiss A, Waitz D, Gabriel M, Traub-Weidinger T, Uprimny C, von Guggenberg E, Decristoforo C, Warwitz B, Widmann G, Virgolini IJ. Putzer D, et al. Eur J Nucl Med Mol Imaging. 2013 Feb;40(3):364-72. doi: 10.1007/s00259-012-2286-6. Epub 2012 Nov 14. Eur J Nucl Med Mol Imaging. 2013. PMID: 23151915

6

Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.

Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME. Wild D, et al. J Nucl Med. 2013 Mar;54(3):364-72. doi: 10.2967/jnumed.112.111724. Epub 2013 Jan 7. J Nucl Med. 2013. PMID: 23297077 Free article. Clinical Trial.

7

Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.

Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, Pacak K, Marx SJ, Kebebew E. Sadowski SM, et al. J Clin Oncol. 2016 Feb 20;34(6):588-96. doi: 10.1200/JCO.2015.64.0987. Epub 2015 Dec 28. J Clin Oncol. 2016. PMID: 26712231 Free PMC article.

8

Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours.

Van Binnebeek S, Vanbilloen B, Baete K, Terwinghe C, Koole M, Mottaghy FM, Clement PM, Mortelmans L, Bogaerts K, Haustermans K, Nackaerts K, Van Cutsem E, Verslype C, Verbruggen A, Deroose CM. Van Binnebeek S, et al. Eur Radiol. 2016 Mar;26(3):900-9. doi: 10.1007/s00330-015-3882-1. Epub 2015 Jul 12. Eur Radiol. 2016. PMID: 26162577 Clinical Trial.

9

68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.

Etchebehere EC, de Oliveira Santos A, Gumz B, Vicente A, Hoff PG, Corradi G, Ichiki WA, de Almeida Filho JG, Cantoni S, Camargo EE, Costa FP. Etchebehere EC, et al. J Nucl Med. 2014 Oct;55(10):1598-604. doi: 10.2967/jnumed.114.144543. Epub 2014 Aug 28. J Nucl Med. 2014. PMID: 25168627 Free article.

10

Visual and whole-body quantitative analyses of ⁶⁸ Ga-DOTATATE PET/CT for prognosis of outcome after PRRT with ¹⁷⁷Lu-DOTATATE.

Hotta M, Sonni I, Thin P, Nguyen K, Gardner L, Ciuca L, Hayrapetian A, Lewis M, Lubin D, Allen-Auerbach M. Hotta M, et al. Ann Nucl Med. 2024 Apr;38(4):296-304. doi: 10.1007/s12149-023-01899-w. Epub 2024 Jan 22. Ann Nucl Med. 2024. PMID: 38252228

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

228 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 30850506

228 results

Results by year